What are analysts Suggestions on Pieris Pharmaceuticals, Inc.(NASDAQ:PIRS): Synovus Financial Corp.(NYSE:SNV)

0
7

Pieris Pharmaceuticals, Inc. (PIRS) will report its next earnings on Nov 07 BMO. The company reported the earnings of $0/Share in the last quarter where the estimated EPS by analysts was $-0.01/share. The difference between the expected and actual EPS was $0.01/share, which represents an Earnings surprise of 100%.

Many analysts are providing their Estimated Earnings analysis for Pieris Pharmaceuticals, Inc. and for the current quarter 5 analysts have projected that the stock could give an Average Earnings estimate of $-0.12/share. These analysts have also projected a Low Estimate of $-0.17/share and a High Estimate of $-0.03/share.

In case of Revenue Estimates, 5 analysts have provided their consensus Average Revenue Estimates for Pieris Pharmaceuticals, Inc. as 7.41 Million. According to these analysts, the Low Revenue Estimate for Pieris Pharmaceuticals, Inc. is 4.4 Million and the High Revenue Estimate is 12.4 Million. The company had Year Ago Sales of 3.93 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for PIRS to be 6.3%. They are projecting Next Quarter growth of -200%. For the next 5 years, Pieris Pharmaceuticals, Inc. is expecting Growth of -56.63% per annum, whereas in the past 5 years the growth was -22.5% per annum.

Some buy side analysts are also providing their Analysis on Pieris Pharmaceuticals, Inc., where 2 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Pieris Pharmaceuticals, Inc. might touch $12 high while the Average Price Target and Low price Target is $10.67 and $8 respectively.

Pieris Pharmaceuticals, Inc. closed its last trading session at $4.38 with the loss of -13.47%. The Market Capitalization of the company stands at 204.6 Million. The Company has 52-week high of $9.75 and 52-week low of $3.98. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -18.58% where SMA50 and SMA200 are -25.08% and -37.55% respectively. The Company Touched its 52-Week High on 02/13/18 and 52-Week Low on 11/07/18.

The Relative Volume of the company is 5.28 and Average Volume (3 months) is 404.02 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -6.3%. The Return on Equity (ROE) value stands at -27.8%. While it’s Return on Investment (ROI) value is -136.5%.

While looking at the Stock’s Performance, Pieris Pharmaceuticals, Inc. currently shows a Weekly Performance of -8.01%, where Monthly Performance is -23.74%, Quarterly performance is -30.07%, 6 Months performance is -31.83% and yearly performance percentage is -20.21%. Year to Date performance value (YTD perf) value is -49.8%. The Stock currently has a Weekly Volatility of 9.76% and Monthly Volatility of 7.93%.

Synovus Financial Corp. (SNV) will report its next earnings on Oct 23 BMO. The company reported the earnings of $0.84/Share in the last quarter where the estimated EPS by analysts was $0.92/share. The difference between the expected and actual EPS was $-0.08/share, which represents an Earnings surprise of -8.7%.

Many analysts are providing their Estimated Earnings analysis for Synovus Financial Corp. and for the current quarter 14 analysts have projected that the stock could give an Average Earnings estimate of $0.93/share. These analysts have also projected a Low Estimate of $0.88/share and a High Estimate of $0.96/share.

In case of Revenue Estimates, 10 analysts have provided their consensus Average Revenue Estimates for Synovus Financial Corp. as 370.96 Million. According to these analysts, the Low Revenue Estimate for Synovus Financial Corp. is 368.1 Million and the High Revenue Estimate is 373.7 Million. The company had Year Ago Sales of 339.06 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for SNV to be 30.6%. They are projecting Next Quarter growth of 8.14%. For the next 5 years, Synovus Financial Corp. is expecting Growth of 11.73% per annum, whereas in the past 5 years the growth was 44.27% per annum.

Some buy side analysts are also providing their Analysis on Synovus Financial Corp., where 1 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 2 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Synovus Financial Corp. might touch $56.5 high while the Average Price Target and Low price Target is $49.63 and $42 respectively.

Synovus Financial Corp. closed its last trading session at $38.16 with the gain of 0.24%. The Market Capitalization of the company stands at 4.48 Billion. The Company has 52-week high of $57.40 and 52-week low of $36.24. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -4.24% where SMA50 and SMA200 are -14.23% and -23.63% respectively. The Company Touched its 52-Week High on 06/11/18 and 52-Week Low on 10/26/18.

The Relative Volume of the company is 1.32 and Average Volume (3 months) is 1.62 million. The company’s P/E (price to earnings) ratio is 11.92 and Forward P/E ratio of 9.5.

The company shows its Return on Assets (ROA) value of 0.9%. The Return on Equity (ROE) value stands at 10.4%. While it’s Return on Investment (ROI) value is 23.5%.

While looking at the Stock’s Performance, Synovus Financial Corp. currently shows a Weekly Performance of 1.84%, where Monthly Performance is -15.99%, Quarterly performance is -22.9%, 6 Months performance is -29.22% and yearly performance percentage is -16.14%. Year to Date performance value (YTD perf) value is -20.21%. The Stock currently has a Weekly Volatility of 2.39% and Monthly Volatility of 3.37%.

SHARE